(lp0
S'Windtree Announces Successful Completion of Second and Final AEROSURF Phase ... PR Newswire  - Apr 11, 2017 WARRINGTON, Pa., April 11, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that the AEROSURF&nbsp;...Windtree Therapeutics blows higher on positive phase 2b trial news - Proactive Investors USA & CanadaWindtree Therapeutics Inc.  Rise Continues - StockNewsUnion'
p1
aS'Discovery Labs Changes Name to Windtree Therapeutics, Inc.  PR Newswire  - Apr 18, 2016 WARRINGTON, Pa., April 18, 2016 /PRNewswire/ -- Discovery Laboratories, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has changed its&nbsp;...Bucks biotech firm changes its name - Philadelphia Business Journal'
p2
aS'Buy Windtree Therapeutics For Its Innovative AEROSURF Technology. Seeking Alpha - May 3, 2016 In this article, we are initiating coverage on Windtree Therapeutics , , a company that is focused on its proprietary synthetic surfactant  that is delivered non-invasively using novel ...'
p3
aS'Windtree Therapeutics Completes $10.5 Million Private Offering PR Newswire  - Feb 15, 2017 15, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it has completed a $10.5 million private placement&nbsp;...'
p4
aS'Windtree Therapeutics, Inc.  Receives Nasdaq Listing Notification StreetInsider.com - Nov 18, 2016 Windtree Therapeutics, Inc.  disclosed the following in a U.S. SEC filing on Friday: Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.'
p5
aS"How Windtree Therapeutics Inc's  384.1% ROE Fares Against The Industry? Simply Wall St - Apr 14, 2017 While Windtree Therapeutics Inc's  384.1% ROE was above the industry average of 27.88%, the role of leverage must also be considered."
p6
aS'Windtree Therapeutics Preclinical Study Results Show Potential for KL4 ... PR Newswire  - Nov 3, 2016 3, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, announced today that recently presented preclinical data at the 62nd&nbsp;...'
p7
aS'Windtree Therapeutics Announces FDA Fast Track Designation for AEROSURF PR Newswire  - Sep 19, 2016 WARRINGTON, Pa., Sept. 19, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that the U.S.'
p8
aS'Windtree Therapeutics to Host Key Opinion Leader Meeting on Respiratory ... PR Newswire  - Jun 7, 2016 WARRINGTON, Pa., June 7, 2016 /PRNewswire/ -- Windtree Therapeutics, Inc. , a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, today announced that it will host a Key Opinion&nbsp;...'
p9
aS'Zacks: Windtree Therapeutics Inc  Given Consensus Rating of &quot;Strong Buy ... BBNS - 5 hours ago Windtree Therapeutics logo Shares of Windtree Therapeutics Inc  have received an average broker rating score of 1.00  from the two analysts that cover the stock, Zacks Investment Research reports.'
p10
a.